The Future Directions Across the Spectrum of Breast Cancer

CME Activities

• Clinical Updates in Hereditary Breast Cancer: Highlights From Vienna 2023
  Medscape Education, March 2023
  Do you know how to select the optimal treatment for a patient with early breast cancer who is eligible for PARP inhibitor and CDK4/6 inhibitor therapy?
  0.25 CME
• Optimizing Adjuvant Treatment of Early Breast Cancer: Where Are We Today?
  Medscape Education, March 2023
  PARP inhibitors, CDK4/6 inhibitors, immunotherapy, and SERDS: Can you select optimal treatments for early breast cancer (EBC)? And what might be the consensus at St. Gallen?
  0.50 CME
• HER2 Testing in 2023: Case Studies for Pathologists
  Medscape Education, March 2023
  Are you up to date with the latest guidance and best practices in breast cancer human epidermal growth factor receptor 2 (HER2) testing? Learn more here!
  1.00 CME
• The Evolution of HER2 Therapies in Breast Cancer
  Medscape Education, November 2022
  Did you know that human epidermal growth factor receptor 2 (HER2) was among the first targets in breast cancer? Join the experts for the history of HER2 therapies and future outlook.
  0.75 CME
• Two Decades of HER2 Targeting: The Unfinished Revolution in Breast Cancer
  Medscape Education, November 2022
  Did you know we can tailor human epidermal growth factor receptor 2 (HER2) therapy to patient’s risk profile without compromising outcomes?
  1.25 CME
• The Pathologist's Role in Improving Outcomes for Patients With HER2-Expressing Breast Cancer
  Medscape Education, October 2022
  Did you know that up to 55% of breast cancers have low human epidermal growth factor receptor 2 (HER2) expression? Join the experts in discussing implications of HER2-low in breast cancer.
  0.50 CME
• The Surgical Voice in Early-Stage High-Risk Breast Cancer
  Medscape Education Oncology, October 2022
  Do you know which team member plays the most pivotal role in ensuring early-stage breast cancer patients receive vital gene testing?
  0.25 CME
• Breast Cancer Expert Voices from Paris
  Medscape Education, October 2022
  Are you up to date with the latest breast cancer data? Or looking to further understand its implications? Watch these expert perspectives for insight.
  0.50 CME
• Anticipating Advances in Breast Cancer at the Upcoming Oncology Congress in Paris
  Medscape Education, September 2022
  Have you chosen your priority abstracts for the next European oncology congress? Listen to this expert audio commentary for some additional insights.
• Clinical Cases in Breast Cancer: Expert Guidance to Optimize Outcomes
  Medscape Education, August 2022
  The past months have produced a plethora of practice-changing clinical data and approvals in the field of breast cancer. Are you up to date?
  0.50 CME
• Clinical Implications of the Latest Advances in Breast Cancer From Chicago 2022
  Medscape Education, August 2022
  Missed the latest breast cancer updates from Chicago or want to better understand their practice implications? Watch our expert-led session.
  0.75 CME
• Clinical Updates in Breast Cancer: Highlights From Chicago 2022
  Medscape Education, June 2022
  Are you aware of the new practice-changing clinical data transforming breast cancer care?
  0.50 CME
• Clinical Perspectives on HER2-Targeted Antibody-Drug Conjugates: Treatment-Related Adverse Events
  Medscape Education, June 2022
  Do you know how to safely manage treatment-related adverse events (TRAEs) associated with human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs)?
  0.50 CME
• Best Practices and New Developments in Breast Cancer
  Medscape Education, June 2022
  The therapeutic landscape for breast cancer is vast, with a plethora of new clinical data to be presented at the upcoming Chicago meeting. Are you prepared?
  0.50 CME
• Optimizing Patient Outcomes With Antibody-Drug Conjugates for HER2-Positive Cancers
  Medscape Education, May 2022
  Antibody-drug conjugates (ADCs) are revolutionizing cancer treatment, but do you know how to manage adverse events related to human epidermal growth factor receptor 2 (HER2)-targeted ADCs?
  0.50 CME
• Addressing the Challenge of HER2 Heterogeneity in Breast Cancer
  Medscape Education, May 2022
  Did you know that there is a paradigm shift in the definition of human epidermal growth factor receptor 2 (HER2) status in breast cancer?
  0.50 CME

SABCS Conference 360

• Management of HR+ Breast Cancer: Changing Paradigms by Maximizing the Clinical Potential of Therapeutic Targets
  Medscape Education, February 2023
  Are you aware of the clinical potential of novel therapeutic targets and emerging evidence for hormone receptor-positive (HR+) breast cancer?
  1.25 CME

  1.25 ABIM MOC
• Breast Cancer Therapies: Interrogating the Data From San Antonio 2022
  Medscape Education, January 2023
  Did you know that the efficacy of SERDs in ER+/HER2- metastatic breast cancer differs according to length of prior CDK4/6 inhibitor treatment?
  0.50 CME
• Breast Cancer Snapshots From San Antonio 2022
  Medscape Education, December 2022
  Are you aware of the latest clinical research devoted to improving diagnosis and treatment of breast cancer?
  0.50 CME
• A Preview of the San Antonio 2022 Meeting for Breast Cancer
  Medscape Education, November 2022
  What are the anticipated highlights for the upcoming SABCS 2022 meeting? Join Dr Müller for expert insights on the latest developments.